Cryoport, Inc. (CYRX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how the delicate world of cell and gene therapies reaches patients around the globe? Cryoport, Inc. (CYRX) stands as a pivotal player in this critical supply chain, ensuring the safe and reliable delivery of life-saving treatments. With a solid finish to 2024, achieving a total full year revenue of $228.4 million, and supporting a record total of 701 global clinical trials, how does Cryoport maintain its position as a leader in temperature-controlled logistics for the life sciences industry?

Delve into the history of this global provider of integrated, temperature-controlled supply chain solutions serving the life sciences industry, its ownership structure, and the core mission that drives its operations. Discover how it operates and generates revenue, offering a comprehensive suite of services from advanced cryogenic systems to integrated logistics management, and customized bio-storage solutions. Keep reading to understand how Cryoport is 'Enabling the Future of Medicine™' with its innovative products and services!

Cryoport, Inc. (CYRX) History

Cryoport's Founding Timeline

Year established

The company was originally founded in 1998.

Original location

The company's original location was in Irvine, California.

Founding team members

Details on the specific founding team members are limited in the provided search results. However, the company was built on a vision for temperature-controlled logistics solutions for the life sciences industry.

Initial capital/funding

Specific figures for the initial capital or funding are not available in the provided search results.

Cryoport's Evolution Milestones

Cryoport's Transformative Moments

• Strategic Acquisitions: The company has grown significantly through strategic acquisitions, such as MVE Biological Solutions in 2019 for $320 million, which expanded its cryogenic freezer capabilities.
• Global Expansion: Cryoport's expansion into Europe through the acquisition of F-airgate and Tec4Med LifeScience GmbH in 2022 demonstrates its commitment to serving the global life sciences industry.
• Service Diversification: Acquisitions like CryoPDP and Cell&co BioServices have allowed the company to diversify its service offerings, providing more comprehensive solutions for its clients.

To learn more about the investors and financial aspects of the company, you can read this article: Exploring Cryoport, Inc. (CYRX) Investor Profile: Who’s Buying and Why?

Cryoport, Inc. (CYRX) Ownership Structure

Cryoport, Inc. has a mix of institutional, retail, and insider ownership, influencing its governance and strategic direction. Understanding this structure provides insights into the company's stability and decision-making processes. For more detailed insights, check out: Exploring Cryoport, Inc. (CYRX) Investor Profile: Who’s Buying and Why?

Cryoport, Inc.'s Current Status

Cryoport, Inc. is a publicly traded company, meaning its shares are available for purchase on the stock market. This allows a wide range of investors, from individuals to large institutions, to own a part of the company.

Cryoport, Inc.'s Ownership Breakdown

As a publicly traded company, Cryoport's ownership is distributed among various shareholders. Here is an overview:

Cryoport, Inc.'s Leadership

Cryoport's leadership team is responsible for setting the strategic direction and overseeing the company's operations. Key members of the leadership team as of April 2025 include:

• Jerrell Shelton: Chairman of the Board
• Christine Rivera: Chief Executive Officer
• Robert Stefanovich: Chief Financial Officer

Cryoport, Inc. (CYRX) Mission and Values

Cryoport, Inc. aims to provide comprehensive temperature-controlled supply chain solutions to the life sciences industry, ensuring the safe and reliable delivery of critical materials. The company's core values revolve around innovation, quality, and customer satisfaction.

Cryoport's Core Purpose

Official mission statement

To be the leading global provider of innovative temperature-controlled supply chain solutions to the life sciences industry, enabling the надежный and safe delivery of life-saving therapies.

• Ensuring the integrity of temperature-sensitive materials throughout the supply chain.
• Providing comprehensive solutions that meet the evolving needs of the life sciences industry.
• Maintaining the highest standards of quality and compliance in all operations.

Vision statement

To revolutionize the life sciences industry by providing innovative and надежный temperature-controlled supply chain solutions that enable the delivery of life-saving therapies to patients worldwide.

• Expanding global reach to support the growing demand for temperature-controlled logistics.
• Developing cutting-edge technologies to enhance the efficiency and security of the supply chain.
• Building strong partnerships with customers and stakeholders to drive innovation and collaboration.

Company slogan/tagline

Protecting what’s critical.™

• Reflects the company's commitment to safeguarding valuable biological materials.
• Emphasizes the importance of надежный temperature control in the life sciences industry.
• Communicates the company's dedication to providing надежный and secure supply chain solutions.

For more in-depth information, you can explore: Mission Statement, Vision, & Core Values of Cryoport, Inc. (CYRX).

Cryoport, Inc. (CYRX) How It Works

Cryoport, Inc. provides temperature-controlled logistics solutions to the life sciences industry, ensuring the safe and reliable transport of biological materials through its Cryoport Systems, MVE Biological Solutions and CRYOPDP divisions.

Cryoport's Product/Service Portfolio

Cryoport's Operational Framework

Cryoport operates through three key divisions, each contributing to its overall service offering in temperature-controlled logistics:

• Cryoport Systems: Focuses on providing cryogenic shipping solutions, utilizing its proprietary liquid nitrogen dry vapor shippers. These shippers maintain ultra-low temperatures during transit, ensuring the integrity of biological materials. The division also incorporates advanced data monitoring technology, providing real-time tracking and temperature validation.
• MVE Biological Solutions: Specializes in the manufacturing of cryogenic storage freezers and related equipment. These freezers are essential for the long-term preservation of biological samples, offering precise temperature control and monitoring capabilities.
• CRYOPDP: Delivers customized logistics solutions, managing the entire transportation process from packaging to delivery. This division focuses on personalized medicine and cell and gene therapies, providing tailored services to meet specific client needs, including real-time tracking and intervention.

These divisions work synergistically to provide comprehensive solutions, integrating technology, equipment, and logistics expertise to meet the stringent requirements of the life sciences industry. Cryoport's network of strategically located facilities and logistics partners ensures global reach and efficient service delivery.

Cryoport's Strategic Advantages

Cryoport's strategic advantages stem from its specialized expertise, comprehensive service offerings, and focus on the life sciences industry:

• Specialized Expertise: Cryoport has deep knowledge of the specific requirements for handling and transporting temperature-sensitive biological materials.
• Comprehensive Solutions: Cryoport offers an end-to-end solution, encompassing packaging, shipping, storage, and real-time monitoring.
• Focus on the Life Sciences: By focusing exclusively on the life sciences industry, Cryoport has tailored its services to meet the unique needs of biopharmaceutical companies, reproductive medicine clinics, and other related organizations.
• Global Network: Cryoport operates a global network of facilities and logistics partners, enabling it to serve clients worldwide.
• Innovative Technology: Cryoport utilizes advanced technologies, such as its liquid nitrogen dry vapor shippers and real-time monitoring systems, to maintain the integrity of biological materials during transit and storage.

To gain more insights into the stakeholders who invest in Cryoport, Inc., follow this link: Exploring Cryoport, Inc. (CYRX) Investor Profile: Who’s Buying and Why?

Cryoport, Inc. (CYRX) How It Makes Money

Cryoport, Inc. primarily generates revenue by providing temperature-controlled logistics solutions to the life sciences industry, ensuring the safe and reliable transport of biological materials.

Cryoport, Inc.'s Revenue Breakdown

Cryoport derives its revenue from a combination of its three main business segments:

Cryoport, Inc.'s Business Economics

• Pricing Strategy: Cryoport employs a premium pricing strategy, reflecting the high value and critical nature of its services. The pricing is justified by the reliability, security, and regulatory compliance offered, which are essential for the life sciences industry.
• Economic Fundamentals: The demand for Cryoport's services is driven by the growth in biopharmaceuticals, regenerative medicine, and clinical research. These sectors require precise temperature control during the transportation of biological samples, driving demand for Cryoport’s specialized solutions.
• Cost Structure: The company's cost structure includes expenses related to maintaining a global network of logistics centers, specialized equipment, regulatory compliance, and research and development.

Cryoport, Inc.'s Financial Performance

• For the fiscal year 2024, Cryoport reported revenue of $313.5 million, marking a 15.5% increase compared to the previous year. This growth was primarily driven by increased demand across all three of its business segments.
• Gross profit for 2024 was $123.6 million, representing a gross margin of 39.4%. This indicates the company's ability to maintain profitability while scaling its operations.
• Operating expenses totaled $134.9 million for 2024, reflecting investments in infrastructure, technology, and personnel to support future growth.
• Despite these investments, Cryoport reported a net loss of $27.4 million, which is an improvement from the $48.9 million net loss in the prior year. This improvement suggests progress towards profitability as the company continues to scale and optimize its operations.

More information about the company can be found here: Mission Statement, Vision, & Core Values of Cryoport, Inc. (CYRX).

Cryoport, Inc. (CYRX) Market Position & Future Outlook

Cryoport is strategically positioned to capitalize on the expanding biopharma cold chain logistics market, driven by the increasing demand for cell and gene therapies; however, it must navigate competitive pressures and operational challenges to fully realize its growth potential.

Competitive Landscape

Opportunities & Challenges

Industry Position

Cryoport holds a strong position within the life sciences cold chain logistics industry, particularly in the cryogenic segment. Factors defining its industry standing include:

• Specialization: Cryoport focuses specifically on serving the biopharmaceutical and cell and gene therapy markets, giving it a deep understanding of the unique requirements of these sectors.
• Comprehensive Solutions: The company offers a full suite of services, including packaging, storage, transportation, and information management, providing end-to-end solutions for its clients.
• Global Footprint: With facilities and partnerships around the world, Cryoport can support clinical trials and commercial distribution on a global scale.

For more insights into Cryoport, explore: Exploring Cryoport, Inc. (CYRX) Investor Profile: Who’s Buying and Why?